The Lancet Neurology
Издатель: Elsevier · ISSN 1474-4422 · 43 статей
- Dravet syndrome: modifying disease across the lifespan
- Bridging the gap between dementia risk factors and interventions
- CSF dynamics in idiopathic normal pressure hydrocephalus
- GBA1 Parkinson's disease: peculiarities in Asia and India
- CAR T-cell trials paused after three deaths
- Safety and efficacy of daily oral edaravone (FNP122) in patients with amyotrophic lateral sclerosis (ADORE): a multicentre, double-blind, phase 3, randomised controlled trial
- Early middle meningeal artery embolisation plus standard treatment versus standard treatment alone for chronic subdural haematoma in France (OTEMACS): a randomised, open-label, controlled trial
- Application of the 2024 McDonald multiple sclerosis criteria in the international Acute Optic Neuritis Network (ACON): a cross-sectional cohort study
- Dravet syndrome: clinical features across the lifespan, molecular findings, and therapeutic approaches
- Neuropathic pain: advances in diagnosis, mechanisms, and treatment
- Alzheimer's disease testing needs evidence, ethics, and equity
- Targeting orexin signalling in narcolepsy
- HIMALAYA: learning from another negative phase 2 trial in ALS
- Finding more intracranial aneurysms that will never rupture
- Charting the future of biomarkers and therapy in Alzheimer's disease
- Brain capital versus brain capitalism
- Traumatic brain injury in China: the next classification
- A new era for neuroimmunology in Africa
- Correction to Lancet Neurol 2026; 25: 654–63
- Correction to Lancet Neurol 2026; 25: 781–88
- The Evolving Brain: How to Thrive in a World We Weren't Made For, Paul Goldsmith. Headline Publishing Group (2026), 400, ISBN: 9781035426461
- Safety, tolerability, and efficacy of alixorexton, a selective orexin 2 receptor agonist for narcolepsy type 1 (Vibrance-1): a randomised, double-blind, placebo-controlled, phase 2 trial
- Safety, tolerability, and efficacy of RIPK1 inhibitor, SAR443820, in amyotrophic lateral sclerosis (HIMALAYA): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
- Prevalence of unruptured intracranial aneurysms according to comorbidities, risk factors, country, and time period: a systematic review and meta-analysis
- Fluid biomarkers in the evolving care landscape of Alzheimer's disease and related disorders
- Neuroimaging in the era of biologically defined Alzheimer's disease and disease-modifying therapy
- Clinical pathways for cognitively unimpaired individuals with Alzheimer's disease neuropathological change
- Degenerative cervical myelopathy: early detection and the potential for preventing disability
- The clinical relevance of multiple sclerosis genetics: from susceptibility to disease severity and progression
- Neurotrauma as a chronic disease: a call for integrated care